CDK4/6 Inhibitor Efficacy in ESR1-Mutant Metastatic Breast Cancer.

doi:10.1056/EVIDoa2300231

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

CDK4/6 Inhibitor Efficacy in ESR1-Mutant Metastatic Breast Cancer.

NEJM evidence - 1 May 2024

Lloyd Maxwell R, Brett Jamie O, Carmeli Ariel, Weipert Caroline M, Zhang Nicole, Yu Junhua, Bucheit Leslie, Medford Arielle J, Wagle Nikhil, Bardia Aditya, Wander Seth A

Abstract excerpt

BACKGROUND: In estrogen receptor-positive metastatic breast cancer, ESR1 mutations (ESR1m) are a common mechanism of acquired resistance to aromatase inhibitors (ArIh). However, the impact ESR1 alterations have on CDK4/6 inhibitor (CDK4/6i) sensitivity has not been established. Analyses of CDK4/6i trials suggest that the endocrine therapy partner and specific ESR1 allele may affect susceptibility. We analyzed a...

Read the complete abstract on PubMed